Tiziana’s foralumab meets primary endpoints in Phase 2a multiple sclerosis trial
TLSA•Tiziana Life Sciences said its Phase 2a trial of intranasal foralumab in non-active secondary progressive multiple sclerosis met both primary endpoints. The lower dose significantly reduced neuroinflammation versus placebo, while fatigue improved from baseline with both doses.
1. Trial results
Tiziana Life Sciences said its Phase 2a INFORM-MS trial met both primary endpoints. The lower dose significantly reduced neuroinflammation versus placebo, but the higher dose did not; fatigue improved significantly from baseline with both doses, and disability scores did not change during treatment. Both doses were safe and well tolerated. The company plans to present detailed findings at a future scientific congress and discuss further development with the FDA.
